Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Inspiration Biopharmaceuticals Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A

November 18, 2010 By Bio-Medicine.Org

LAGUNA NIGUEL, Calif., Nov. 19, 2010 /PRNewswire/ — Inspiration
Biopharmaceuticals, Inc. (Inspiration) today announced the Company
has initiated treatment of patients in a pivotal clinical study of
OBI-1, an intravenous recombinant porcine factor VIII (FVIII)
product, for the treatment of acquired hemophilia A, a rare, though
potentially life-threatening bleeding disorder.  Based on a
partnership agreement signed with Ipsen SA (Euronext: IPN; ADR:
IPSEY) in January 2010, Inspiration has received a $50 million
milestone payment by Ipsen.  In return, Inspiration has issued
to Ipsen a note, which may be converted to Series C preferred
stock, bringing Ipsen’s fully diluted share ownership position in
Inspiration to 34%.

Under the terms of the agreement, Inspiration in-licensed OBI-1
from Ipsen, and is responsible for the clinical development,
regulatory approval and commercialization of the product.
 Inspiration is developing OBI-1 for the treatment of
individuals with acquired hemophilia A and individuals with
congenital hemophilia A who have developed inhibitors against human
FVIII.

Dr. Anne Greist, at the Indiana Hemophilia and Thrombosis
Center, in Indianapolis, Indiana, stated, “Acquired hemophilia is a
condition in which patients develop antibodies against their own
coagulation factors.  Affecting men and women equally,
acquired hemophilia can lead to a life-threatening crisis for
patients.  Unfortunately, current therapies are often
inadequate to stop these types of acute bleeding episodes, and new
innovative therapeutic approaches are needed.  We are pleased
to have been the first site in the U.S. to enroll a patient in the
pivotal study of OBI-1, a promising and important new product
candidate in the treatment of acquired hemophilia.”

Michael Griffith, Ph.D., President and CEO of Inspiration,
commented, “We are excited to report the initiation of our pivotal
clinical trial of OBI-1, one of two product candi

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech